List of Studies ( Metabolite:GalCer 18:1;O2/18:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
|---|---|---|---|---|---|---|---|
| ST001820 | AN002955 | WT neurons treated with APOE3/3 and APOE4/4 ACM | Neurons | Mouse | Alzheimers disease | Columbia University | area under the curve |
| ST002453 | AN004002 | APOE modulates microglial immunometabolism in response to age, amyloid pathology, and inflammatory challenge (Part 3 of 3) | Brain | Mouse | Inflammation | University of Kentucky | Intensity per pixel |
| ST000797 | AN001268 | Targeted Galactosyl Sphingolipids Concentrations of Myelin to Enhance Recovery of Function after SCI | Spinal cord | Mouse | Spinal cord injury | Mayo Clinic | ng/vial |
| ST000852 | AN001376 | Targeting Myelin Galactosyl Sphingolipids of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI | Spinal cord | Mouse | Spinal cord injury | Mayo Clinic | ng/vial |
| ST000859 | AN001384 | Targeted Galactosyl Sphingolipid Concentration in Kallikrein 6 Mice after SCI | Spinal cord | Mouse | Spinal cord injury | Mayo Clinic | ng/vial |
| ST000916 | AN001495 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | nM |
| ST000917 | AN001501 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | nM |
| ST000915 | AN001489 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | pmol/mg |
